Browsing tag:

hypertension


As an immunosuppressant drug used to prevent transplant rejection, Sirolimus, CAS number 53123-88-9, is a macrolide. Particularly useful for kidney transplant patients, sirolimus is also known as the brand name Rapamune, which is marketed by Pfizer. The first patent for Rapamune is set to expire in October 2012. An addtional patent will expire in July[…]

Read More

  Telmisartan, CAS number 144701-48-4, an Anti-Hypertensive research molecule, is also an approved TEVI API for compounding purposes, offered here from LGM Pharma. Indicated for the treatment of hypertension, telmisartan is known as the brand name Micardis, which is marketed by Boehringer Ingelheim Pharmaceuticals. As an angiotensin II receptor antagonist telmisartan is effective at preventing[…]

Read More

Valsartan  is used as a treatment for high blood pressure, as well as congestive heart failure. As part of a class of medications called angiotensin II receptor antagonists, valsartan impedes the action of natural substances in the body that cause a tightening of blood vessels, thus allowing a smoother blood flow to the heart. Also[…]

Read More

Dorzolamide Hydrochloride is an eye drop indicated for the treatment of ocular hypertension and open angle glaucoma. Also known by the trade names Trusopt and Cosopt, Dorzolamide Hydrochloride works by inhibiting the isoenzyme carbonic anhydrase, also termed CA-II. This inhibition helps to decrease the amount of fluid made within the eye, thus decreasing pressure in the affected[…]

Read More

As of December 7, 2011 the Oncologic Drugs Advisory Committee voted to approve Axitinib CAS# 319460-85-0 (Inlyta) as a second-line treatment for patients with Advanced Renal Cell Carcinoma. This unanimous vote was based upon the findings of the phase 3 trial done in 2010, which compared Axitinib and Sorafenib. Axitinib, when compared to Sorafenib in[…]

Read More

Patients with pulmonary hypertension can look at Treprostinil and breathe a sigh of relief. For years, this type of hypertension has been managed by a limited choice of treatment options such as oxygen, vasodilators and prostaglandins. These two treatment options are used to “open up” the arteries which results in reduced pressure in the blood[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service